Andres Gutierrez

Company: Advaxis

Seminars:

Clinical Activity & Immunogenicity of a Neoantigen Immunotherapy in Non-Small Cell Lung Cancer 4:30 pm

An off-the-shelf, Listeria based-neoantigen immunotherapy (ADXS-503) has been developed using 22 most prevalent tumor associated antigens in NSCLC Dose escalation with monotherapy and in combination with pembrolizumab have been conducted A dose expansion cohort using ADXS-503 as an add-on-therapy to pembrolizumab at progression, has shown potential to reverse resistance to the checkpoint inhibitorRead more

day: Day One